CSL Shares Marginally Higher on Influenza Vaccine Study Data

MT Newswires Live

2025/10/22

CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.

Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.

A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.

A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577438714"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577438714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577438714?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577438714","market":"sg","top_or_hot":-1,"title":"CSL Shares Marginally Higher on Influenza Vaccine Study Data","media":"MT Newswires Live","content":"<html><body><p> CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.</p><p>Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.</p><p>A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.</p><p>A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Shares Marginally Higher on Influenza Vaccine Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Shares Marginally Higher on Influenza Vaccine Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-22 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.</p><p>Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.</p><p>A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.</p><p>A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL.AU","symbol_name":"CSL LIMITED","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577438714","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577438714","pubTimestamp":1761097234,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL's  shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines  and high-dose quadrivalent influenza vaccines  was comparable across all settings.Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL.AU":"CSL LIMITED","BK7067":"生物科技","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7508":"医药生物股","CSL":"卡莱尔伙伴","BK7511":"ESG概念","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7501":"新冠治疗股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4086":"建筑产品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"CSL股价因流感疫苗研究数据小幅走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}